ENHANCED ANTI-TUMOR EFFICACY BY COMBINATION OF CHECKPOINT IMMUNOTHERAPY AND ANTIBODYDRUG CONJUGATES UTILIZING THE TOPOISOMERASE I INHIBITOR LINKER-PAYLOAD AZ'0133

被引：0

作者：

Omar, Bilal ^{[1
]}

Arbitman, Steve ^{[1
]}

Daita, Kalyani ^{[1
]}

Paucarmayta, Ana ^{[1
]}

Chow, Huiyanangel ^{[1
]}

Anderton, Judith ^{[1
]}

Rothstein, Raymond ^{[1
]}

Gerber, Allison ^{[1
]}

Mulgrew, Kathy ^{[1
]}

Wetzel, Leslie ^{[1
]}

Rosfjord, Edward ^{[1
]}

Luheshi, Nadia ^{[1
]}

Kinneer, Krista ^{[1
]}

Hammond, Scott ^{[1
]}

机构：

[1] AstraZeneca, Gaithersburg, MD USA

来源：

JOURNAL FOR IMMUNOTHERAPY OF CANCER | 2022年 / 10卷

关键词：

D O I：

10.1136/jitc-2022-SITC2022.0895

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

895

引用

页码：A932 / A932

页数：1

共 16 条

[1] Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Llopiz, Diana
Ruiz, Marta
Villanueva, Lorea
Iglesias, Tamara
Silva, Leyre
Egea, Josune
Lasarte, Juan J.
Pivette, Perrine
Trochon-Joseph, Veronique
Vasseur, Berangere
Dixon, Graham
Sangro, Bruno
Sarobe, Pablo
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2019, 68 (03) : 379 - 393
[2] Enhanced anti-tumor efficacy of checkpoint inhibitors in combination with the histone deacetylase inhibitor Belinostat in a murine hepatocellular carcinoma model
Diana Llopiz
Marta Ruiz
Lorea Villanueva
Tamara Iglesias
Leyre Silva
Josune Egea
Juan J. Lasarte
Perrine Pivette
Véronique Trochon-Joseph
Bérangère Vasseur
Graham Dixon
Bruno Sangro
Pablo Sarobe
Cancer Immunology, Immunotherapy, 2019, 68 : 379 - 393
[3] Enhanced anti-tumor efficacy of a checkpoint inhibitor in combination with the HDAC inhibitor belinostat in a murine hepato-cellular carcinoma preclinical model
Llopiz, Diana
Ruiz, Marta
Pivette, Perrine
Trochon-Joseph, Veronique
Vasseur, Berangere
Lemarchand, Caroline
Dixon, Graham
Sarobe, Pablo
Sangro, Bruno
CANCER RESEARCH, 2017, 77
[4] An exatecan derivative based linker-payload platform leads to ADC products with promising anti-tumor efficacy and potential low interstitial lung disease (ILD) risk
Lin, S.
Shi, R.
Li, B.
Qiu, Y.
Hua, H.
Zhang, Y.
EUROPEAN JOURNAL OF CANCER, 2022, 174 : S91 - S91
[5] The selective WEE1 inhibitor azenosertib shows synergistic anti-tumor effects in combination with topoisomerase I inhibitor-based antibody drug conjugates
Ma, J.
Guo, X.
Lee, C.
Meric-Bernstam, F.
Harismendy, O.
Jubb, A.
Kim, D.
Lackner, M. R.
ANNALS OF ONCOLOGY, 2024, 35 : S225 - S226
[6] The topoisomerase I inhibitor gimatecan exhibits anti-tumor activity against malignant glioma xenografts as single agent and in combination
Vassal, G.
Hamelin, N.
Opolon, P.
Versace, R.
Geoerger, B.
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
[7] PERK INHIBITOR HC-5404 DEMONSTRATES IMMUNEACTIVATION AND ANTI-TUMOR EFFICACY IN COMBINATION WITH ANTI-PD1 IMMUNE CHECKPOINT INHIBITOR ANTIBODY
Chan, Anissa S. H.
Drees, Jeremy
Li, Yunfang
Kangas, Takashi
Zhang, Weiyu
Fumagalli, Maria
Dewji, Iman
Qiu, Xiaohong
Collette, Nick
Harrison, Ben
LaCayo, Ashley
Vidal, Veronica Calvo
Dudgeon, Crissy
Stokes, Michael
Lightcap, Eric
Surguladze, David
Bose, Nandita
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A921 - A921
[8] Enhanced Anti-Tumor Efficacy through a Combination of Integrin αvβ6-Targeted Photodynamic Therapy and Immune Checkpoint Inhibition
Gao, Liquan
Zhang, Chenran
Gao, Duo
Liu, Hao
Yu, Xinhe
Lai, Jianhao
Wang, Fan
Lin, Jian
Liu, Zhaofei
THERANOSTICS, 2016, 6 (05): : 627 - 637
[9] Obatoclax, the pan-Bcl-2 inhibitor sensitizes hepatocellular carcinoma cells to promote the anti-tumor efficacy in combination with immune checkpoint blockade
Li, Jingye
Xu, Jinrong
Li, Zhibing
TRANSLATIONAL ONCOLOGY, 2021, 14 (08):
[10] Combination immunotherapy integrating HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment for improved T cell recruitment and anti-tumor efficacy
Rao, Aparna
Kawabe, Mayumi
Taylor, Jennifer
Storkus, Walter
JOURNAL OF IMMUNOLOGY, 2012, 188

← 1 2 →